Egrifta (Tesamorelin) Satisfaction Trends Over Time: Real Results, Reddit, and Reviews
HealthRX.com
Reddit reports on Egrifta satisfaction are mixed and anecdotal
Key numbers
- 2 mgDaily tesamorelin dose given to people with HIV and excess abdominal fat in the 412-patient trial, for 26 weeksSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 15.2%Fall in visceral fat on tesamorelin over 26 weeks in the 412-patient trial, vs a 5.0% rise on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- -10.9%Change in visceral fat at six months on tesamorelin in the 404-patient phase 3 trial, vs -0.6% on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- Approval / FDA-approved November 10, 2010 (BLA 022505) for excess abdominal fat in HIV-positive adults with lipodystrophy [3][4]
- Current products / Egrifta SV 1.4 mg and Egrifta WR 1.28 mg, once daily under the skin; not substitutable [4][5]
- 26-week VAT / fell 15.2% on tesamorelin vs a 5.0% rise on placebo in the 412-patient trial [1]
- Stopping / VAT +16% to +22% from week 26 to 52 after switching to placebo, vs about 0% to -5% on continued tesamorelin [4]
Is there any published data on how patients rate Egrifta?
In the two randomized phase 3 trials, body image was a secondary outcome [1][2]. The FDA label reports adverse reaction rates rather than patient ratings [4]. Tesamorelin is approved only for excess abdominal fat in HIV-associated lipodystrophy, and the label says it is not indicated for weight loss because its effect on weight is neutral [4].
Questions worth asking
What the trials measured
In the phase 3 trials, the primary outcome was visceral adipose tissue (VAT) measured by CT. The studies also assessed body image and metabolic measures such as triglycerides and IGF-1 [1][2].
In the 412-patient trial (Falutz et al., NEJM 2007), people with HIV and excess abdominal fat received 2 mg of tesamorelin or placebo daily for 26 weeks [1]. VAT fell 15.2% on tesamorelin and rose 5.0% on placebo; triglycerides fell 50 mg/dL vs a 9 mg/dL rise; IGF-1 rose 81.0% vs a 5.0% fall (P<0.001 for all) [1]. The second phase 3 trial (404 patients) found VAT changes of -10.9% vs -0.6% at six months, P<0.0001 [2].
What happens after week 26, and what the label lists
The trials also followed VAT between weeks 26 and 52. People who stayed on tesamorelin held their week-26 VAT roughly where it was, changing by about 0% in one study and -5% in the other, while people re-randomized to placebo gained back 22% and 16% respectively [4].
Injection-site reactions were 25% on tesamorelin vs 14% on placebo during the first 26 weeks. In the combined table, arthralgia was 13% vs 11%, myalgia 6% vs 2%, and peripheral edema 6% vs 2% [4]. HbA1c of 6.5% or higher developed in 5% on tesamorelin vs 1% on placebo, hazard ratio 3.3 (95% CI 1.4 to 9.6) [4].
Bottom line
By week 26, people taking tesamorelin had less visceral fat and higher IGF-1 than those on placebo [1]. The label lists joint pain, injection-site reactions, fluid retention and raised glucose among the effects seen in the trials [4].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
What did the trials measure besides visceral fat?
How fast does tesamorelin change abdominal fat?
Does the fat come back after stopping Egrifta?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How long does it take to get results from tesamorelin?
The phase 3 trials measured results at 26 weeks. In the 412-patient trial, visceral fat fell 15.2% on tesamorelin while it rose 5.0% on placebo. Fat changes were also tracked after week 26, when people switched to placebo gained back 16% to 22% of visceral fat by week 52.
Can tesamorelin cause weight gain?
The label says tesamorelin's effect on weight is neutral and that it is not indicated for weight loss. Fluid retention was among the effects seen in the trials, with peripheral edema at 6% on tesamorelin vs 2% on placebo.
References
Show all 7 referencesHide references
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
- Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22.
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
- World Anti-Doping Agency.